CRISPR Therapeutics could be a standout winner this year, we said on April 13.
We also noted, “Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target, with the firm expecting CRSP to get a nod for its gene-editing therapy, exa-cel.”
At the time, CRSP traded around $44. Today, it’s up to $63.90 after hitting a high of $71.20 just last week. All as the company’s broad pipeline of next-generation therapies show promise. For example, CRSP and partner Vertex Pharmaceuticals just recently submitted exa-cel as a treatment for transfusion-dependent beta-thalassemia and severe sickle cell disease in the U.S., the EU, and the United Kingdom.
CRSP also said its immuno-oncology assets CTX112 and CTX131, along with CTX310, which targets ANGPTL3, are all poised to take the next steps in their respective developmental programs.
According to a company press release, “We continue to drive our portfolio programs, including the initiation of clinical trials for our next-generation CAR T candidates, CTX112 and CTX131. In addition, we expect to advance CTX310, our lead in vivo program targeting ANGPTL3, into clinical trials later this year. We are well-positioned to drive towards our mission of bringing transformative and potentially curative therapies to patients in need.”
Further progress could send CRSP to higher highs.
